Noninvasive assessment of cell proliferation in ovarian cancer using [18F] 3′deoxy-3-fluorothymidine positron emission tomography/computed tomography imaging

Nuclear Medicine and Biology

Volumn 38, Issue 4, 2011, Pages 485-491

  Richard, Scott D ^a   Bencherif, Badreddine ^b   Edwards, Robert P ^a   Elishaev, Esther ^a,b   Krivak, Thomas C ^b   Mountz, James M ^b   DeLoia, Julie A ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

18FLT; Cell proliferation; Ki67; Ovarian cancer; PET CT

Indexed keywords

3' FLUOROTHYMIDINE F 18; CA 125 ANTIGEN; CARBOPLATIN; CD34 ANTIGEN; KI 67 ANTIGEN; MESSENGER RNA; PACLITAXEL; THYMIDINE KINASE;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER STAGING; CELL PROLIFERATION; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FIBROADENOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; MALIGNANT NEOPLASTIC DISEASE; MITOSIS INDEX; NON INVASIVE PROCEDURE; OVARY CANCER; OVARY CARCINOMA; PELVIS TUMOR; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT CANCER; TUMOR BIOPSY;

AGED; BIOLOGICAL TRANSPORT; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; OVARIAN NEOPLASMS; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; THYMIDINE KINASE; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 79955469908     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.12.003     Document Type: Article

References (25)

1. American Cancer Society surveillance research statistics American Cancer Society http://www.cancer.org.
2. Cannistra S.A. Cancer of the ovary. N Engl J Med 2004, 351(24):2519-2529.
3. Dauplat J., Le Bouedec G., Pomel C., Scherer C. Cytoreductive surgery for advanced stages of ovarian cancer. Semin Surg Oncol 2000, 19(1):42-48.
4. Rustin G., Tuxen M. Use of CA125 in follow-up of ovarian cancer patients. Lancet 1996, 348(9021):191-192.
5. Nilof N.M., Knapp R.C., Lavin P.T., et al. The CA125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gynecol 1986, 155:56-60.
6. Vergote I.B., Bormer O.P., Abeler V.M. Evaluation of CA125 levels in monitoring of ovarian cancer. Am J Obstet Gynecol 1987, 157:88-92.
7. De Rosa V., Mangoni di Stefano M.L., Brunetti A., et al. Computed tomography and second-look surgery in ovarian cancer patients. Correlation, actual role, and limitations of CT scan. Eur J Gynaecol Oncol 1995, 16(2):123-129.
8. Yen T.C., Lai D.H. Positron emission tomography in gynecologic cancer. Semin Nucl Med 2006, 36(1):93-104.
9. Thrall M.M., Deloia J.A., Gallion H., Avril N. Clinical use of combined positron emission tomography and computed tomography in recurrent ovarian cancer. Gynecol Oncol 2007, 105:17-22.
10. Fenchel S., Grab D., Nuessle K., et al. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology 2002, 223(3):780-788.
11. Romer W., Avril N., Dose J., et al. Metabolic characterization of ovarian tumors with positron emission tomography and F-18 fluorodeoxyglucose. Rofo 1997, 166(1):62-68.
12. Shields A.F., Grierson J.R., Dohmen B.M., et al. Imaging proliferation in vivo with (F-18) FLT and positron emission tomography. Nat Med 1998, 4:1334-1336.
13. Mier W., Haberkorn U., Eisenhunt M. (18F) FLT: portrait of a proliferation marker. Eur J Nucl Med 2002, 29:165-169.
14. Kong X.B., Zhu Q.Y., Vidal P.M., et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'deoxythymidine and 3'-azido-3'deoxythymidine. Antimicrob Agents Chemother 1992, 36(4):808-818.
15. Rasey J.S., Grierson J.R., Wiens L.W., et al. Validation of FLT uptake as a measure of thymidine kinase 1 activity in A549 carcinoma cells. J Nucl Med 2002, 3:1210-1217.
16. Vesselle H., Grierson J., Muzi M., et al. In vivo validation of 3'-deoxy-3'-(18F) fluorothymidine as a proliferation imaging tracer in humans: correlation of (18F) FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002, 8:3315-3323.
17. Buck A.K., Schirrmeister H., Hetzel M., et al. 3'-deoxy-3'(18F) fluorothymidine positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002, 62:3331-3334.
18. Saga T., Kawashima H., Araki N., et al. Evaluation of primary brain tumors with FLT-PET: usefulness and limitations. Clin Nucl Med 2006, 31:774-780.
19. Machulla H.J., Blocher A., Kuntzsch M., Piert M., Wei R., Grierson J.R. Simplified labeling approach for synthesizing 3'-deoxy-3'-(18F)fluorothymidine ((18F) FLT). J Radioanal Nucl Chem 2000, 243:843-846.
20. Francis D.L., Visvikis D., Costa D.C., et al. Potential impact of (18F)3'-deoxy-3'-fluorothymidine versus (18F)fluoro-2-deoxy-d-glucose in positron emission tomorgraphy for colorectal cancer. Eur J Nucl Med Mol Imaging 2003, 30:988-994.
21. Wieder H.A., Geinitz H., Rosenberg R., et al. PET imaging with (18F)3'-deoxy-3'-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging 2007, 34:878-883.
22. Yap C.S., Czernin J., Fishbein M.C., et al. Evaluation of thoracic tumor with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest 2006, 129:393-401.
23. Buck A.K., Halter G., Schirrmeister H., et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 2003, 44:1426-1431.
24. Cobben D.C., Jager P.L., Elsinga P.H., et al. 3'-18Fluoro-3'-deoxy-l-thymidine: a new tracer for staging metastatic melanoma?. J Nucl Med 2003, 44:1927-1932.
25. Cobben D.C., van der Laan B.F., Maas B., et al. 18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET. J Nucl Med 2004, 45:226-231.